What is hepatocellular carcinoma in medical coding: Hepatocellular carcinoma (HCC) is a primary malignant tumor arising from hepatocytes, the main functional cells of the liver, and is coded in ICD-10-CM using code C22.0, which specifically identifies liver cell carcinoma originating in the liver itself.
What HCC means in a billing context: In medical coding, HCC refers to both the clinical diagnosis of hepatocellular carcinoma and its role in Hierarchical Condition Category risk adjustment models, where accurate diagnosis capture directly affects Medicare Advantage reimbursement, patient risk scoring, and plan payment reconciliation.
What separates C22.0 from related codes: C22.0 is used only when the physician has confirmed primary liver cancer originating in liver cells. It is not appropriate for metastatic liver disease from another primary site, intrahepatic bile duct carcinoma, or unspecified liver malignancies, each of which carries its own distinct ICD-10 code and clinical implications.
Key Takeaway: The single most common documentation failure in HCC coding is the absence of a clearly stated diagnosis in the physician note. Coders cannot assign C22.0 based on imaging findings alone. The diagnosis must be explicitly documented by the treating or consulting physician before the code is applied.
Key Takeaway: Misclassifying primary liver cancer as secondary or metastatic disease is a sequencing error with real consequences. It distorts clinical records, affects HCC risk adjustment scores, and can trigger payer audits when treatment patterns do not align with the coded diagnosis.
Key Takeaway: In Medicare Advantage and managed care risk models, hepatocellular carcinoma carries significant HCC category weight. Underreporting this diagnosis, or reporting it with unspecified codes when more specific ones are supported, reduces RAF scores, suppresses plan revenue, and misrepresents the patient’s true disease burden.
ICD-10 Codes Used for Hepatocellular Carcinoma and Related Liver Conditions
Accurate code selection begins with understanding the full landscape of ICD-10 codes that apply to hepatocellular carcinoma, related liver malignancies, underlying risk factors, and treatment encounters. Using the wrong code from this group is one of the most auditable errors in oncology billing.
| ICD-10 Code | Description | Clinical Use Case |
|---|---|---|
| C22.0 | Liver cell carcinoma | Primary hepatocellular carcinoma confirmed by physician |
| C22.1 | Intrahepatic bile duct carcinoma | Cholangiocarcinoma, not HCC |
| C22.2 | Hepatoblastoma | Rare pediatric liver tumor |
| C22.8 | Malignant neoplasm of overlapping liver sites | Tumor involving multiple hepatic subsites |
| C22.9 | Malignant neoplasm of liver, unspecified | When documentation does not specify tumor type |
| C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct | Liver metastasis from another primary site |
| Z85.05 | Personal history of malignant neoplasm of liver | Resolved HCC, surveillance encounters |
| Z51.11 | Encounter for antineoplastic chemotherapy | Chemotherapy administration visit |
| Z51.12 | Encounter for antineoplastic immunotherapy | Immunotherapy administration visit |
| B18.1 | Chronic viral hepatitis B without delta-agent | HBV as underlying risk factor or comorbidity |
| B18.2 | Chronic viral hepatitis C | HCV as underlying risk factor or comorbidity |
| K74.60 | Unspecified cirrhosis of liver | Cirrhosis documented as related condition |
The critical distinction coders must apply is between C22.0 and C22.9. If documentation supports primary liver cell carcinoma, C22.9 is never appropriate. Defaulting to an unspecified code when a specific one is supported creates audit risk and undercodes the actual clinical picture.
How ICD-10-CM Classifies Hepatocellular Carcinoma Within the Neoplasm Structure
ICD-10-CM places hepatocellular carcinoma within Chapter 2, Neoplasms (C00 to D49), under the subcategory C22, which covers malignant neoplasms of the liver and intrahepatic bile ducts. Understanding the hierarchical structure of this category prevents misassignment among related liver cancers.
The broader coding hierarchy is:
- C00 to C75: Malignant neoplasms of specified organs and sites
- C22: Malignant neoplasm of liver and intrahepatic bile ducts
- C22.0: Liver cell carcinoma (hepatocellular carcinoma)
This classification system matters operationally because payers, cancer registries, and risk adjustment models all use the full code specificity to categorize the condition. A C22.0 and a C22.9 are not interchangeable in payer systems, even if they belong to the same parent category.
Primary vs. Secondary Liver Cancer: The Classification Coders Get Wrong Most Often
Primary liver cancer originates in the liver itself. Secondary liver cancer is metastatic disease that traveled to the liver from another organ. The distinction determines which ICD-10 code applies, how the record is sequenced, and how the condition is interpreted in risk adjustment models.
| Characteristic | Primary Liver Cancer (HCC) | Secondary Liver Cancer (Metastasis) |
|---|---|---|
| Origin | Liver cells (hepatocytes) | Another organ, typically colon, lung, or breast |
| Primary ICD-10 code | C22.0 | C78.7 |
| Risk factors | Hepatitis B or C, cirrhosis, NAFLD | Existing cancer at another site |
| Sequencing position | Listed first if reason for encounter | Listed with the primary site code |
| HCC risk adjustment category | High-weight HCC category | Metastatic cancer category |
When a patient has colorectal cancer with liver metastases, the correct approach is to code the primary colorectal malignancy and add C78.7 for the liver involvement. Coding C22.0 in that scenario is a factual error that misrepresents the patient’s diagnosis and may trigger a payer audit when oncology treatment patterns do not align.
Documentation Requirements That Drive Accurate HCC Coding
Documentation is where most coding failures begin. A technically correct ICD-10 code applied to a poorly documented record is still a compliance risk. Coders should not assign C22.0 unless the treating or consulting physician has documented the diagnosis clearly. Imaging findings, elevated alpha-fetoprotein levels, or radiologist impressions do not independently justify code assignment.
The minimum documentation that should be present before assigning C22.0 includes:
- Explicit physician documentation confirming hepatocellular carcinoma as the diagnosis
- Pathology report from biopsy or surgical specimen, or a clinical diagnosis based on imaging criteria per established guidelines when biopsy is not performed
- Imaging report (CT, MRI, or ultrasound) describing the hepatic lesion and its characteristics
- Oncology consultation note when applicable
- Assessment and plan entry in the encounter note addressing the active cancer diagnosis
- Treatment plan or monitoring documentation connecting the diagnosis to the current encounter
- Laboratory results (AFP levels) supporting the clinical picture where documented
One commonly missed documentation element is the distinction between active disease and a history of disease. If the physician documents HCC in the history section of a note without addressing it in the assessment and plan, the coder cannot treat it as an active billable diagnosis for that encounter. The diagnosis must be actively managed, monitored, or assessed during the visit to be coded as current.
What Coders Should Query the Physician About
When documentation is ambiguous, the appropriate response is a clinical documentation integrity query, not a code assignment based on inference. Common query triggers for hepatocellular carcinoma include:
- Imaging describes a liver lesion consistent with HCC but the physician note does not explicitly confirm the diagnosis
- The record references prior HCC without clarifying whether the condition is currently active or resolved
- The note documents treatment for liver cancer without specifying primary versus metastatic origin
- Elevated AFP is noted but no connection to a confirmed diagnosis is documented
- Documentation mentions cirrhosis and a liver mass but does not confirm malignancy
ICD-10 Sequencing Rules for Hepatocellular Carcinoma Encounters
Sequencing determines which diagnosis appears first on the claim and, in many cases, which DRG or payment tier applies. The principal diagnosis is the condition established after study to be chiefly responsible for the admission or encounter.
For an inpatient admission primarily for hepatocellular carcinoma treatment, C22.0 is listed as the principal diagnosis. Related conditions such as cirrhosis (K74.60), viral hepatitis (B18.1 or B18.2), or treatment codes (Z51.11) are added as secondary diagnoses in an order that reflects clinical complexity and reporting requirements.
Sequencing rules that billing teams frequently miss:
- Chemotherapy encounters: When the encounter is specifically for chemotherapy administration, Z51.11 is sequenced first, and the malignancy code (C22.0) follows as the reason for the treatment. This is a specific ICD-10-CM guideline that differs from typical sequencing logic.
- Symptom coding: Signs and symptoms routinely associated with a confirmed malignancy should not be coded separately when the confirmed diagnosis is documented. Abdominal pain or weight loss in a patient with documented HCC are not separately billable in most cases.
- Comorbidity sequencing: Cirrhosis, hepatitis B, and hepatitis C should be coded when documented as present and managed during the encounter, even if they are not the primary reason for the visit. These conditions add clinical complexity and support medical necessity.
- History codes: Z85.05 applies only after the HCC has been treated and the physician documents the condition as resolved, in remission, or in the history section with no active treatment. Using Z85.05 for an active cancer is a significant coding error.
Common Coding Errors That Lead to Denials and Audits
Most HCC coding errors fall into predictable patterns. Recognizing these failure points is the fastest way to reduce claim denials and protect revenue integrity.
Defaulting to Unspecified Codes When Specificity Is Supported
Assigning C22.9 when documentation clearly supports C22.0 is a specificity failure. Payers and auditors reviewing oncology records expect the most specific code available when documentation supports it. Repeated use of C22.9 in a practice that treats HCC patients triggers coding accuracy reviews and may result in prepayment scrutiny.
Coding Metastatic Disease as Primary HCC
A patient with colorectal cancer and liver metastases is not an HCC patient. Assigning C22.0 in that scenario creates a factually incorrect diagnosis record, distorts HCC risk category capture, and will not align with the treatment pattern when payers review clinical data alongside claims. The correct code for liver metastasis is C78.7, with the primary malignancy coded and sequenced appropriately.
Coding From Imaging Reports Without Physician Confirmation
Radiology reports are not physician diagnoses. An imaging impression that reads “findings consistent with hepatocellular carcinoma” does not authorize the coder to assign C22.0. The treating or ordering physician must confirm the diagnosis in their own documentation before the code is applied.
Failing to Report Underlying Conditions That Drive Clinical Complexity
Chronic hepatitis B, chronic hepatitis C, and cirrhosis are present in a large majority of HCC patients. When these conditions are documented and actively managed, failing to code them leaves clinical complexity unreported, which affects severity scoring, DRG weight in inpatient settings, and risk adjustment capture for managed care populations.
Using Active Cancer Codes for Surveillance Encounters After Treatment
Once a physician documents HCC as resolved, excised, or in remission following definitive treatment, the active malignancy code is no longer appropriate. Continuing to use C22.0 on post-treatment surveillance encounters when the physician has documented resolution creates a compliance vulnerability that can surface in audits.
Ignoring the Encounter-Level Purpose in Sequencing
Billing teams that build claim templates without verifying encounter purpose frequently sequence the malignancy code when the purpose of the visit was actually chemotherapy administration. That sequencing error changes the expected claim structure and can result in a denial or processing delay that requires manual correction.
HCC in Risk Adjustment Coding: Why Diagnosis Accuracy Has a Revenue Impact
Hepatocellular carcinoma is included in the CMS Hierarchical Condition Category framework as a high-acuity diagnosis. In Medicare Advantage and other managed care risk adjustment models, accurately capturing this diagnosis each applicable period contributes to the patient’s Risk Adjustment Factor score, which determines the plan payment rate for that member.
Underreporting hepatocellular carcinoma, or reporting it with low-specificity codes that fail to map to the correct HCC category, suppresses RAF scores. For Medicare Advantage plans and delegated provider organizations, this creates a direct revenue gap. For provider groups under value-based care arrangements, it misrepresents the complexity of the patient population and can distort quality and utilization metrics.
The operational requirement in risk adjustment is that each condition must be diagnosed, documented, and coded in each measurement period. A prior year’s capture does not carry forward automatically. The diagnosis must be substantiated with current-period documentation to be counted in the current year’s risk score.
Practices that treat HCC patients under Medicare Advantage contracts should audit their annual well-visit documentation and all oncology encounter notes to confirm that active hepatocellular carcinoma is addressed and coded during each performance period.
Step-by-Step Workflow for Coding a Hepatocellular Carcinoma Encounter
This workflow applies to outpatient encounters involving confirmed hepatocellular carcinoma. Inpatient sequencing follows UHDDS guidelines, but the documentation review steps are the same.
- Confirm the encounter purpose: Determine whether the visit is for diagnosis, treatment, chemotherapy administration, immunotherapy, surgical consultation, follow-up, or surveillance. This governs sequencing.
- Locate the physician’s diagnosis statement: Confirm that the physician’s assessment and plan contains an explicit diagnosis of hepatocellular carcinoma. Do not rely solely on the problem list, imaging, or prior visit notes.
- Identify primary versus secondary disease: Verify whether the documented HCC is primary liver cancer (C22.0) or whether the liver involvement is metastatic from another site (C78.7). This requires review of the full record, not just the current note.
- Identify active versus historical status: Confirm that the condition is active in the current encounter. If the physician addresses it only as a resolved history, use Z85.05 and do not assign C22.0.
- Identify relevant comorbidities: Review for documented cirrhosis, hepatitis B, hepatitis C, or other conditions that were managed or evaluated during the encounter.
- Assign and sequence codes: Apply C22.0 as the primary diagnosis when the encounter is for HCC management. Apply Z51.11 first when the encounter is specifically for chemotherapy, followed by C22.0. Add comorbidity codes in clinical complexity order.
- Review for specificity and query opportunities: If documentation is ambiguous about primary versus secondary origin, active versus historical status, or diagnosis confirmation, initiate a physician query before claim submission.
- Validate against payer-specific guidelines: Some Medicare Administrative Contractors and commercial payers have local coverage policies relevant to oncology billing. Confirm that documentation supports medical necessity under applicable coverage policies.
Frequently Asked Questions About HCC Medical Coding
What is the correct ICD-10 code for hepatocellular carcinoma?
The correct ICD-10-CM code for confirmed primary hepatocellular carcinoma is C22.0, Liver cell carcinoma. This code applies when a physician has explicitly documented primary liver cancer originating in hepatocytes. It is not appropriate for secondary liver disease or unspecified liver malignancies.
Is the ICD-10 code for hepatoma the same as the code for hepatocellular carcinoma?
Yes. Hepatoma and hepatocellular carcinoma refer to the same clinical entity and both map to ICD-10-CM code C22.0. The terms are used interchangeably in clinical documentation, and coders should recognize both as synonyms for the same primary liver malignancy.
When should C22.9 be used instead of C22.0?
C22.9, Malignant neoplasm of liver unspecified, should only be used when documentation confirms a liver malignancy but does not specify whether it is hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, or another type. If the physician documents HCC or liver cell carcinoma, C22.0 is the appropriate and required code.
Can coders assign C22.0 based on an imaging report alone?
No. Imaging reports are diagnostic tools, not physician diagnoses. A radiologist’s impression that findings are consistent with HCC does not authorize the coder to assign C22.0. The treating physician must confirm the diagnosis in their own documentation before the code applies.
What is the difference between C22.0 and C78.7?
C22.0 identifies primary hepatocellular carcinoma, meaning the malignancy originated in the liver. C78.7 identifies secondary malignant neoplasm of the liver, meaning the cancer spread to the liver from a primary site elsewhere in the body, such as the colon, lung, or breast. These codes are mutually exclusive based on disease origin and should never be applied interchangeably.
How does hepatocellular carcinoma coding affect Medicare Advantage risk adjustment?
Hepatocellular carcinoma maps to a high-acuity Hierarchical Condition Category in the CMS-HCC model. Accurately capturing and coding this diagnosis during each measurement period supports the patient’s RAF score, which directly influences plan payment rates. Failing to capture the diagnosis in a given year suppresses that year’s risk score regardless of prior-year captures.
What codes should be reported alongside C22.0 for an HCC patient with cirrhosis and hepatitis C?
When the physician documents active cirrhosis and chronic hepatitis C in a patient with HCC, the appropriate additional codes are K74.60 for unspecified cirrhosis of liver and B18.2 for chronic viral hepatitis C. These comorbidities should be reported when documented and when they are managed or evaluated during the encounter.
Should Z85.05 or C22.0 be used for a patient in surveillance after HCC treatment?
Z85.05, Personal history of malignant neoplasm of liver, applies when the physician documents the HCC as resolved, successfully treated, or no longer active. C22.0 should not be used for post-treatment surveillance encounters once the physician has documented the cancer as resolved or in remission. Using the active malignancy code after documented resolution is a compliance error.
Next Steps for Billing Teams Managing HCC Coding Accuracy
- Audit a sample of recent claims coded with C22.0 and C22.9 to verify that documentation supports the specificity of each code assigned
- Review encounter notes for HCC patients to confirm physician diagnosis statements appear in the assessment and plan, not only in the problem list or history
- Establish a documentation query protocol for ambiguous cases involving liver lesions, unconfirmed diagnoses, or unclear primary versus secondary status
- Confirm that chemotherapy and immunotherapy encounters are sequenced with Z51.11 or Z51.12 first per ICD-10-CM official guidelines
- Verify that comorbid conditions including cirrhosis and chronic hepatitis are being consistently captured when documented and applicable to the encounter
- Review all post-treatment surveillance encounters to ensure Z85.05 is applied correctly once the physician documents resolution
- Train billing and coding staff on the distinction between primary HCC (C22.0) and metastatic liver disease (C78.7)
- For Medicare Advantage populations, confirm that HCC diagnoses are captured and supported each performance period with current-year documentation
Get Expert Support for Hepatocellular Carcinoma Coding and Oncology Billing
Hepatocellular carcinoma coding errors are not just compliance risks. They are revenue risks. Incorrect sequencing, unspecified codes, and missed comorbidity capture create denials, suppress risk scores, and generate audit exposure that takes months to resolve. Getting this right requires both coding expertise and a clear documentation process that connects the physician’s clinical record to the correct ICD-10 assignment.
If your team is managing oncology or HCC coding and facing denial patterns, risk adjustment gaps, or documentation quality concerns, our team can help you identify where the breakdowns are occurring and build a more accurate, audit-ready process.
Contact our revenue cycle specialists to discuss hepatocellular carcinoma coding support, oncology billing review, or HCC risk adjustment accuracy for your practice or organization.
